Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab monotherapy as third-line treatment for advanced or metastatic esophageal cancer or Siewert type I gastroesophageal junction adenocarcinoma
MOH_2017-01-03_000003Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) and gastroesophageal junction adenocarcinoma, sponsored by Merck & Co. Started Aug 2016; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2017-01-03_000003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-03_000003.